Core Viewpoint - Morgan Stanley has raised the target price for MicroPort Scientific Corporation (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying the stock as a top choice in China's medical technology sector, indicating that the recent price pullback presents a good buying opportunity [1] Group 1: Company Performance - MicroPort's global order momentum remains strong, with over 170 surgical robot orders accumulated as of last Wednesday, up from 150 orders at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2: Financial Projections - Based on approximately 100 cumulative orders for Toumai, the company has revised its installation forecast for this year from 84 units to 105 units, primarily due to overseas growth and the assumption that orders can be converted to sales within less than a quarter [1] - An improved installation base and product mix, along with an expected gross margin improvement of 1 to 1.5 percentage points, are anticipated [1]

智通财经APP获悉，摩根大通发布研报称，上调对微创机器人-B(02252)目标价，由30.9港元上调至42港 元，此按现金流折现率作估值，投资评级"增持"，重申该股为中国医疗科技股首选，并指股价在基本因 素未变下回调为良好的买入机会。 微创机器人全球订单动力仍然强劲，截至上周三(8日)累计手术机器 人订单逾170套，高于8月底的150套。该行指，Toumai(四臂腔镜手术机器人)安装在全球加速，国际扩 张急速，在近40个国家及主要医院系统应用，推动强劲的采用。 该信息由智通财经网提供 该行基于Toumai累计订单约100套，上调今年完成安装数量预测，由84套上调至105套，主要在海外增 长及假设订单可在少于一季内转化为销售入账。 更高的安装量基础及产品组合改善，以及预期毛利率1 至1.5个百分点改善。 ...